{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:54:22Z","timestamp":1768510462800,"version":"3.49.0"},"posted":{"date-parts":[[2024,2,14]]},"group-title":"Biochemistry","reference-count":65,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Schistosomiasis, or bilharzia, is a neglected tropical disease caused by\n                  <jats:italic>Schistosoma<\/jats:italic>\n                  spp. blood flukes that infects over 200 million people worldwide. Just one partially effective drug is available, and new drugs and drug targets would be welcome. The 20S proteasome is a validated drug target for many parasitic infections, including those caused by\n                  <jats:italic>Plasmodium<\/jats:italic>\n                  and\n                  <jats:italic>Leishmania<\/jats:italic>\n                  . We previously showed that anticancer proteasome inhibitors that act through the\n                  <jats:italic>Schistosoma mansoni<\/jats:italic>\n                  20S proteasome (Sm20S) kill the parasite\n                  <jats:italic>in vitro<\/jats:italic>\n                  . To advance these initial findings, we employed Multiplex Substrate Profiling by Mass Spectrometry (MSP-MS) to define the substrate cleavage specificities of the three catalytic \u03b2 subunits of purified Sm20S. The profiles in turn were used to design and synthesize subunit-specific optimized substrates that performed two to eight fold better than the equivalent substrates used to measure the activity of the constitutive human proteasome (c20S). These specific substrates also eliminated the need to purify Sm20S from parasite extracts - a single step enrichment was sufficient to accurately measure substrate hydrolysis and its inhibition with proteasome inhibitors. Finally, we show that the substrate and inhibition profiles for the 20S proteasome from the three medically important schistosome species are similar, suggesting that data arising from an inhibitor development campaign that focuses on Sm20S can be extrapolated to the other two targets with consequent time and cost savings.\n                <\/jats:p>","DOI":"10.1101\/2024.02.13.580161","type":"posted-content","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T22:45:12Z","timestamp":1707950712000},"source":"Crossref","is-referenced-by-count":2,"title":["Development of subunit selective proteasome substrates for\n                  <i>Schistosoma species<\/i>"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9570-1739","authenticated-orcid":false,"given":"Zhenze","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-3500","authenticated-orcid":false,"given":"Elany B.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4029-0706","authenticated-orcid":false,"given":"Pavla","family":"Fajtov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence J.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3357-0424","authenticated-orcid":false,"given":"Nelly","family":"El-Sakkary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle E.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven C","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3048-8572","authenticated-orcid":false,"given":"Conor R.","family":"Caffrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5695-0409","authenticated-orcid":false,"given":"Anthony J.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024021706550623000_2024.02.13.580161v1.1","first-page":"153","article-title":"Schistosomiasis: Still a Cause of Significant Morbidity and Mortality","volume":"10","year":"2019","journal-title":"Res Rep Trop Med"},{"key":"2024021706550623000_2024.02.13.580161v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61949-2"},{"key":"2024021706550623000_2024.02.13.580161v1.3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-018-0013-8","article-title":"Schistosomiasis","volume":"4","year":"2018","journal-title":"Nature Reviews Disease Primers"},{"key":"2024021706550623000_2024.02.13.580161v1.4","doi-asserted-by":"publisher","DOI":"10.1002\/med.2610030204"},{"key":"2024021706550623000_2024.02.13.580161v1.5","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.15.27"},{"key":"2024021706550623000_2024.02.13.580161v1.6","first-page":"187","volume-title":"Neglected Tropical Diseases: Drug Discovery and Development","volume":"77","year":"2019"},{"key":"2024021706550623000_2024.02.13.580161v1.7","unstructured":"WHO. Preventative chemotherapy in human helminthiasis. Coordinated use of anthelminthic drugs in human interventions: a manual for health professionals and programme managers; Geneva 2006."},{"key":"2024021706550623000_2024.02.13.580161v1.8","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.4269\/ajtmh.19-0843","article-title":"Village Response to Mass Drug Administration for Schistosomiasis in Mwanza Region, Northwestern Tanzania: Are We Missing Socioeconomic, Cultural, and Political Dimensions?","volume":"103","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"2024021706550623000_2024.02.13.580161v1.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-002-0751-z"},{"key":"2024021706550623000_2024.02.13.580161v1.10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13071-016-1958-7","article-title":"Efficacy and safety of praziquantel 40 mg\/kg in preschool-aged and school-aged children: a meta-analysis","volume":"10","year":"2017","journal-title":"Parasit Vectors"},{"key":"2024021706550623000_2024.02.13.580161v1.11","doi-asserted-by":"crossref","first-page":"e0009189","DOI":"10.1371\/journal.pntd.0009189","article-title":"Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): A systematic review and meta-analysis of factors influence its efficacy","volume":"15","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024021706550623000_2024.02.13.580161v1.12","first-page":"2625255","article-title":"Efficacy of Praziquantel for the Treatment of Human Schistosomiasis in Ethiopia: A Systematic Review and Meta-Analysis","volume":"2021","year":"2021","journal-title":"J Trop Med"},{"key":"2024021706550623000_2024.02.13.580161v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4894(86)90184-0"},{"key":"2024021706550623000_2024.02.13.580161v1.14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00811.x"},{"key":"2024021706550623000_2024.02.13.580161v1.15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijpddr.2018.10.004","article-title":"TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling","volume":"8","year":"2018","journal-title":"International journal for parasitology. Drugs and drug resistance"},{"key":"2024021706550623000_2024.02.13.580161v1.16","doi-asserted-by":"crossref","first-page":"110191","DOI":"10.1016\/j.cbi.2022.110191","article-title":"EF24, a schistosomicidal curcumin analog: Insights from its synthesis and phenotypic, biochemical and cytotoxic activities","volume":"368","year":"2022","journal-title":"Chemico-biological interactions"},{"key":"2024021706550623000_2024.02.13.580161v1.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000504"},{"key":"2024021706550623000_2024.02.13.580161v1.18","doi-asserted-by":"crossref","first-page":"933097","DOI":"10.3389\/fitd.2022.933097","article-title":"A review of the genetic determinants of praziquantel resistance in Schistosoma mansoni: Is praziquantel and intestinal schistosomiasis a perfect match?","volume":"3","year":"2022","journal-title":"Fontiers in Tropical Diseases"},{"key":"2024021706550623000_2024.02.13.580161v1.19","doi-asserted-by":"crossref","unstructured":"Danso-Appiah, A. ; Owiredu, D. ; Asiamah, M. ; Akuffo, K. ; Eusebi, P. ; Jiangang, G. ; Mwinzi, P. ; Colley, D. G. ; Hagan, P. ; Murad, M. H. ; Djirmay, A. G . Safety of praziquantel in persons with and without schistosomiasis: systematic review and meta-analysis. medRxiv 2022, 2022.03.09.22270839.","DOI":"10.1101\/2022.03.09.22270839"},{"key":"2024021706550623000_2024.02.13.580161v1.20","unstructured":"Marker, E. J. , Debbert, S.L. Recent Advances in Anti-Schistosomiasis Drug Discovery. Parasitic Helminths and Zoonoses - From Basic to Applied Research 2022."},{"key":"2024021706550623000_2024.02.13.580161v1.21","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1021\/acsinfecdis.9b00237","article-title":"The Proteasome as a Drug Target in the Metazoan Pathogen, Schistosoma mansoni","volume":"5","year":"2019","journal-title":"ACS infectious diseases"},{"key":"2024021706550623000_2024.02.13.580161v1.22","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00436-020-06686-4","article-title":"Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes","volume":"119","year":"2020","journal-title":"Parasitol Res"},{"key":"2024021706550623000_2024.02.13.580161v1.23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-062917-011931"},{"key":"2024021706550623000_2024.02.13.580161v1.24","doi-asserted-by":"publisher","DOI":"10.1042\/BST20200382"},{"key":"2024021706550623000_2024.02.13.580161v1.25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4086"},{"key":"2024021706550623000_2024.02.13.580161v1.26","first-page":"vdab142","article-title":"Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I\/II clinical trial data","volume":"3","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2024021706550623000_2024.02.13.580161v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/nature16936"},{"key":"2024021706550623000_2024.02.13.580161v1.28","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00671"},{"key":"2024021706550623000_2024.02.13.580161v1.29","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14029"},{"key":"2024021706550623000_2024.02.13.580161v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2018.04.007"},{"key":"2024021706550623000_2024.02.13.580161v1.31","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14728222.2019.1685981","article-title":"The proteasome as a target for protozoan parasites","volume":"23","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"2024021706550623000_2024.02.13.580161v1.32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820175116"},{"key":"2024021706550623000_2024.02.13.580161v1.33","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","article-title":"Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases","volume":"63","year":"2020","journal-title":"J Med Chem"},{"key":"2024021706550623000_2024.02.13.580161v1.34","doi-asserted-by":"crossref","first-page":"e1010058","DOI":"10.1371\/journal.ppat.1010058","article-title":"Microbial proteasomes as drug targets","volume":"17","year":"2021","journal-title":"PLoS Pathog"},{"key":"2024021706550623000_2024.02.13.580161v1.35","doi-asserted-by":"crossref","unstructured":"Caffrey, C. R. , Steverding, D. , Ferreira, R.S. , de Oliveira, R.B. , O\u2019Donoghue, A.J. , Monti, M. , Ballatore, C. , Bachovchin, K.A. , Ferrins, L. , Pollastri, M.P. , Zorn, K.M. , Foil, D.H. , Clark, A.M. , Mottin, M. , Andrade, C.A. , de Siqueira-Neto, J.L. , Ekins, S . Drug Discovery and Development for Kinetoplastid Diseases. In Burger\u2019s Medicinal Chemistry and Drug Discovery, 8th ed.; Wiley: 2021; pp 255\u2013334.","DOI":"10.1002\/0471266949.bmc235.pub2"},{"key":"2024021706550623000_2024.02.13.580161v1.36","doi-asserted-by":"crossref","first-page":"11776","DOI":"10.1021\/acs.jmedchem.2c00791","article-title":"Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT)","volume":"65","year":"2022","journal-title":"J Med Chem"},{"key":"2024021706550623000_2024.02.13.580161v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2012.09.019"},{"key":"2024021706550623000_2024.02.13.580161v1.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1806109115"},{"key":"2024021706550623000_2024.02.13.580161v1.39","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01161"},{"key":"2024021706550623000_2024.02.13.580161v1.40","doi-asserted-by":"crossref","first-page":"e202203958","DOI":"10.1002\/chem.202203958","article-title":"Development of Potent and Highly Selective Epoxyketone-Based Plasmodium Proteasome Inhibitors","volume":"29","year":"2023","journal-title":"Chemistry"},{"key":"2024021706550623000_2024.02.13.580161v1.41","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.8b06656"},{"key":"2024021706550623000_2024.02.13.580161v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2011.12.014"},{"key":"2024021706550623000_2024.02.13.580161v1.43","doi-asserted-by":"crossref","unstructured":"O\u2019Donoghue, A. J. ; Bibo-Verdugo, B. ; Miyamoto, Y. ; Wang, S. C. ; Yang, J. Z. ; Zuill, D. E. ; Matsuka, S. ; Jiang, Z. ; Almaliti, J. ; Caffrey, C. R. ; Gerwick, W. H. ; Eckmann, L . 20S Proteasome as a Drug Target in Trichomonas vaginalis. Antimicrob Agents Chemother 2019, 63.","DOI":"10.1128\/AAC.00448-19"},{"key":"2024021706550623000_2024.02.13.580161v1.44","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/cbic.201200007","article-title":"The carmaphycins: new proteasome inhibitors exhibiting an alpha,beta-epoxyketone warhead from a marine cyanobacterium","volume":"13","year":"2012","journal-title":"Chembiochem : a European journal of chemical biology"},{"key":"2024021706550623000_2024.02.13.580161v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/nature19339"},{"key":"2024021706550623000_2024.02.13.580161v1.46","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejmech.2013.05.007","article-title":"3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis","volume":"66","year":"2013","journal-title":"Eur J Med Chem"},{"key":"2024021706550623000_2024.02.13.580161v1.47","doi-asserted-by":"publisher","DOI":"10.1021\/jm401178t"},{"key":"2024021706550623000_2024.02.13.580161v1.48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/acsmedchemlett.8b00498","article-title":"Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis","volume":"10","year":"2019","journal-title":"ACS medicinal chemistry letters"},{"key":"2024021706550623000_2024.02.13.580161v1.49","unstructured":"DNDi. https:\/\/dndi.org\/research-development\/portfolio\/gsk245\/"},{"key":"2024021706550623000_2024.02.13.580161v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2182"},{"key":"2024021706550623000_2024.02.13.580161v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2007.05.031"},{"key":"2024021706550623000_2024.02.13.580161v1.52","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1021\/acsinfecdis.3c00081","article-title":"Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022","volume":"9","year":"2023","journal-title":"ACS infectious diseases"},{"key":"2024021706550623000_2024.02.13.580161v1.53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000478"},{"key":"2024021706550623000_2024.02.13.580161v1.54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040014"},{"key":"2024021706550623000_2024.02.13.580161v1.55","doi-asserted-by":"publisher","DOI":"10.2307\/3280632"},{"key":"2024021706550623000_2024.02.13.580161v1.56","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.TIR118.001099"},{"key":"2024021706550623000_2024.02.13.580161v1.57","doi-asserted-by":"publisher","DOI":"10.1021\/mp0700256"},{"key":"2024021706550623000_2024.02.13.580161v1.58","doi-asserted-by":"crossref","unstructured":"Winter, M. B. ; La Greca, F. ; Arastu-Kapur, S. ; Caiazza, F. ; Cimermancic, P. ; Buchholz, T. J. ; Anderl, J. L. ; Ravalin, M. ; Bohn, M. F. ; Sali, A. ; O\u2019Donoghue, A. J. ; Craik, C. S . Immunoproteasome functions explained by divergence in cleavage specificity and regulation. eLife 2017, 6.","DOI":"10.7554\/eLife.27364"},{"key":"2024021706550623000_2024.02.13.580161v1.59","doi-asserted-by":"publisher","DOI":"10.1007\/s004360050310"},{"key":"2024021706550623000_2024.02.13.580161v1.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2004.03.004"},{"key":"2024021706550623000_2024.02.13.580161v1.61","doi-asserted-by":"crossref","first-page":"e2766","DOI":"10.1371\/journal.pntd.0002766","article-title":"Trypsin- and Chymotrypsin-like serine proteases in schistosoma mansoni-- \u2018the undiscovered country\u2019","volume":"8","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2024021706550623000_2024.02.13.580161v1.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2006.09.013"},{"key":"2024021706550623000_2024.02.13.580161v1.63","doi-asserted-by":"crossref","unstructured":"Kirk, C. J. ; Muchamuel, T. ; Wang, J. ; Fan, R. A . Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors. Cells 2021, 11.","DOI":"10.3390\/cells11010009"},{"key":"2024021706550623000_2024.02.13.580161v1.64","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1002\/cbic.202000375","article-title":"Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits","volume":"21","year":"2020","journal-title":"Chembiochem : a European journal of chemical biology"},{"key":"2024021706550623000_2024.02.13.580161v1.65","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1021\/cb5001263","article-title":"Assessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probes","volume":"9","year":"2014","journal-title":"ACS Chem Biol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.02.13.580161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:57:09Z","timestamp":1768456629000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.02.13.580161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":65,"URL":"https:\/\/doi.org\/10.1101\/2024.02.13.580161","relation":{},"subject":[],"published":{"date-parts":[[2024,2,14]]},"subtype":"preprint"}}